10-Q: Liminatus Pharma Completes Business Combination, Faces 'Going Concern' Doubts Amidst Nasdaq Listing

Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) has successfully completed its business combination, leading to its Nasdaq listing, but the company's financial statements raise substantial doubt about its ability to continue as a going concern.

Summary

• Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) consummated its previously announced business combination on April 30, 2025, acquiring Liminatus Pharma, LLC.
• The transaction involved Liminatus Pharma Merger Sub, Inc. merging into Liminatus, and SPAC Merger Sub, Inc. merging into Iris Acquisition Corp.
• In connection with the merger, Iris stockholders redeemed 59,844 Class A Shares for approximately $702,359 at a price of about $11.74 per share.
• The aggregate consideration paid to Liminatus owners was 17.5 million shares of Common Stock, based on a deemed price of $10.00 per share.
• Concurrently with the business combination, the company completed a private placement (PIPE) with an accredited investor, issuing 1,500,000 shares of Common Stock at $10.00 per share, raising $15,000,000.
• The company's Common Stock (LIMN) and Public Warrants (LIMNW) began trading on The Nasdaq Stock Market on May 1, 2025.
• For the three months ended March 31, 2025, the company reported a net loss of $255, primarily due to franchise tax expense, compared to a net loss of $247 for the same period in 2024.
• As of March 31, 2025, the company had total liabilities of $1,060 and an accumulated deficit of $1,060.
• The company's management has expressed substantial doubt about its ability to continue as a going concern for the next twelve months, stating that the combined company's funds are not believed to be sufficient.
• As of May 30, 2025, there were 26,014,633 shares of common stock outstanding.
• The company received a notice from Nasdaq on May 29, 2025, regarding non-compliance with listing rules due to the delayed filing of this 10-Q, but believes it has regained compliance upon filing.

Sentiment

Score: 3

Explanation: The sentiment is low due to the explicit 'going concern' warning, indicating severe financial uncertainty despite the successful completion of the business combination and Nasdaq listing. While the merger and PIPE are positive, the immediate liquidity concern overshadows them.

Positives

• Successful completion of the business combination with Liminatus Pharma, LLC on April 30, 2025.
• Commencement of trading on The Nasdaq Stock Market under the symbols LIMN and LIMNW on May 1, 2025, providing increased liquidity and visibility.
• Secured $15,000,000 through a PIPE investment, providing capital for future operations of the combined entity.
• Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2025.
• The company believes it has regained compliance with Nasdaq listing requirements by filing this Form 10-Q.

Negatives

• The company reported a net loss of $255 for the three months ended March 31, 2025, primarily from franchise tax expense, indicating no substantive revenue-generating operations during the period.
• Accumulated deficit increased to $1,060 as of March 31, 2025, from $805 as of December 31, 2024.
• Management explicitly stated that the funds of the combined company are not believed to be sufficient to allow the company to continue as a going concern for the next twelve months, raising substantial doubt about its ability to continue.
• The company received a notice from Nasdaq for non-compliance due to the delayed filing of this quarterly report, although compliance is believed to be regained.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, as current funds are not believed to be sufficient for the next twelve months.
• The company's future operations are dependent on its ability to raise additional capital, which may not be available on favorable terms or at all.
• As an emerging growth company, the company has elected to use an extended transition period for complying with new or revised financial accounting standards, which may make comparisons with other public companies difficult.
• The company's financial statements for the period covered do not reflect the consummation of the business combination, which occurred subsequent to the period, meaning the reported financial position is not indicative of the combined entity's current state.

Future Outlook

The company explicitly states that it does not believe the funds of the combined company will be sufficient to allow it to continue as a going concern for the next twelve months from the issuance date of these financial statements, raising substantial doubt about its ability to continue operations without additional funding.

Management Comments

• "The Company does not believe the funds of the combined company will be sufficient to allow the company to continue as a going concern twelve months from the issuance date of these unaudited condensed consolidated financial statements. As such, this raises substantial doubt about the Companys ability to continue as a going concern."
• Chris Kim, CEO, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading, and that the financial statements fairly present the financial condition, results of operations, and cash flows.
• Chris Kim also certified that disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2025.

Industry Context

This filing reflects a common trend of special purpose acquisition company (SPAC) mergers bringing private companies, in this case, a pharmaceutical entity, to the public market. The 'going concern' warning, however, highlights the significant capital requirements and inherent financial risks often associated with early-stage biotechnology and pharmaceutical companies, which typically incur substantial R&D and operational expenses before generating significant revenue.

Comparison to Industry Standards

• The company's pre-merger financial results, showing only franchise tax expenses and no revenue, are typical for a shell company formed solely for a SPAC transaction and are not comparable to operating pharmaceutical companies.
• The 'going concern' warning is a critical red flag, indicating a severe liquidity challenge. While many early-stage biotech companies operate at a loss and require continuous funding, an explicit 'going concern' doubt suggests a more immediate and pressing need for capital compared to industry peers with longer cash runways or established funding pipelines.
• The PIPE investment of $15 million, while providing some capital, appears insufficient to alleviate the going concern doubt, suggesting that the company's projected burn rate or future capital needs are substantial relative to this raise, which is not uncommon for companies entering clinical development phases in the pharmaceutical industry.

Corporate Governance

Related Party Transactions

• In November 2022, the company issued 100 shares of common stock for an aggregate purchase price of $10 to Chris Kim, the company's Chief Executive Officer. As of March 31, 2025, no consideration had been received from Mr. Kim for these shares, resulting in a 'Stock subscription receivable' within the stockholders deficit.

Stakeholder Impact

• **Shareholders**: Face significant risk due to the 'going concern' doubt, which could lead to further dilution or loss of investment if additional funding is not secured. However, the Nasdaq listing provides increased liquidity.
• **Employees**: Future employment and operational stability are dependent on the company's ability to secure sufficient funding to continue as a going concern.
• **Creditors**: May face increased risk of non-payment given the 'going concern' warning.
• **Regulatory Bodies (Nasdaq)**: The company's compliance with listing rules was temporarily impacted by a delayed filing, but compliance is believed to be regained.

Next Steps

• The company needs to secure additional funding to address the 'going concern' doubt and support its operations for the next twelve months.
• The company will incur increased expenses as a result of being a public company, relating to legal, financial reporting, accounting, and auditing compliance efforts.
• The company will continue to operate as an emerging growth company, taking advantage of certain exemptions from reporting requirements.

Key Dates

Recommendation

Keywords

Liminatus Pharma, Iris Acquisition Corp, SPAC, Business Combination, Nasdaq Listing, Going Concern, Biotechnology, Pharmaceutical, 10-Q, PIPE Investment, Merger, Public Company